Literature DB >> 25123334

High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.

Ken-ichi Fujita1, Takashi Hirose2, Sojiro Kusumoto3, Tomohide Sugiyama3, Takao Shirai3, Masanao Nakashima3, Yuko Akiyama4, Yasutsuna Sasaki5.   

Abstract

Entities:  

Keywords:  ABCG2; Erlotinib; High exposure; Interstitial lung disease; Pharmacokinetics; Polymorphism

Mesh：

Substances：

Year:  2014        PMID： 25123334     DOI： 10.1016/j.lungcan.2014.07.021

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  4 in total

Review 1.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

2.  MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study.

Authors:  Zhuo-Xun Wu; Qiu-Xu Teng; Yuqi Yang; Nikita Acharekar; Jing-Quan Wang; Min He; Sabesan Yoganathan; Jun Lin; Jian Wang; Zhe-Sheng Chen
Journal:  Acta Pharm Sin B       Date:  2021-12-30       Impact factor: 14.903

3.  Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).

Authors:  Ahmet M Ulusan; Praveen Rajendran; Wan Mohaiza Dashwood; Omer F Yavuz; Sabeeta Kapoor; Trace A Gustafson; Michelle I Savage; Powel H Brown; Shizuko Sei; Altaf Mohammed; Eduardo Vilar; Roderick H Dashwood
Journal:  Cancer Prev Res (Phila)       Date:  2020-12-04

4.  Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.

Authors:  Zhuo-Xun Wu; Yuqi Yang; Guangsuo Wang; Jing-Quan Wang; Qiu-Xu Teng; Lingling Sun; Zi-Ning Lei; Lizhu Lin; Zhe-Sheng Chen; Chang Zou
Journal:  Cancer Sci       Date:  2020-06-29       Impact factor: 6.716
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.